Nsclc Trials in Guangzhou, China
Conditions / Nsclc / Guangzhou, China
Nsclc is a medical condition with active clinical research programs worldwide.
39 total trials for this combination
Showing top 10 of 39 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06778512 | LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer | RECRUITING | — |
| NCT04746924 | A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06107686 | A Study of YL202 in Selected Patients With Advanced Solid Tumors | RECRUITING | PHASE2 |
| NCT02973789 | Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) | COMPLETED | PHASE3 |
| NCT06685718 | A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT05687266 | Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations | ACTIVE_NOT_RECRUITING | — |
| NCT06422143 | Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] | RECRUITING | — |
| NCT06422143 | Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] | RECRUITING | — |
| NCT05687266 | Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations | ACTIVE_NOT_RECRUITING | — |
| NCT07198321 | A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors | NOT_YET_RECRUITING | PHASE1/PHASE2 |